Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.59 |
| ▸ | GAA | P10253 | 4/20 | 0.59 |
| ▸ | GLA | P06280 | 3/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | TNKS2 | Q9H2K2 | 8/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | TNKS | O95271 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.47 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.47 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.47 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.47 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.47 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2795205 | 0.86 | KDM4E (0.67) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL30908192 | 0.81 | TP53 (0.51) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL30908654 | 0.81 | CA12 (0.46) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL8872485 | 0.81 | GRIN2D (0.53) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL15448464 | 0.81 | CA12 (0.46) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL30908532 | 0.81 | TNKS2 (0.46) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL14978967 | 0.81 | KDM4E (0.77) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL15448463 | 0.81 | KDM4E (0.56) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL8873180 | 0.78 | CA12 (0.56) | KDM4EGAAGLAALDH1A1HPGD | |
| SCHEMBL12002193 | 0.78 | KDM4E (0.78) | KDM4EGAAGLAALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024132001-A1 | MULTITARGET NUCLEAR RECEPTOR LIGANDS BASED ON 2-(4-(QUINOLIN-2-YLOXY)PHENOXY)PROPANOIC ACID AND 2-(4-(QUINOXALIN-2-YLOXY)PHENOXY)PROPANOIC ACID FOR THE TREATMENT OF METABOLIC AND LIVER DISEASES | CHARLES UNIVERSITY, FACULTY OF PHARMACY IN HRADEC KRALOVE (CZ) | 2024-06-27 | — | — | WO | disclosed |
| US-20100210836-A1 | SMALL MOLECULE INHIBITORS OF LYMPHOID TYROSINE PHOSPHATASE | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2010-08-19 | — | — | US | disclosed |
| US-RE38970-E1 | Indolyl or indolinyl derivatives and medicinal use thereof as ACAT or lipid peroxidation inhibitors | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2006-02-07 | — | — | US | disclosed |
| EP-0866059-B1 | NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF | KYOTO PHARMA IND (JP) | 2001-12-05 | — | — | EP | disclosed |
| US-6200988-B1 | TETRAHYDROQUINOLINE DERIVATES; INHIBITORS OF ACYL COA:CHOLESTEROL ACYLTRANSFERASE AND LIPOPEROXIDATION; ARTERIOSCLEROSIS: CARDIOVASCULAR AND BRAIN DISORDERS | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2001-03-13 | — | — | US | disclosed |
| US-6063806-A | CARBOXY ACID OR ESTER DERIVATIVES OF INDOLINE OR INDOLE | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 2000-05-16 | — | — | US | disclosed |
| EP-0866059-A1 | NOVEL HETEROCYCLIC DERIVATIVES AND MEDICINAL USE THEREOF | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1998-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100210836-A1 | SMALL MOLECULE INHIBITORS OF LYMPHOID TYROSINE PHOSPHATASE | PTPRCAP, PTPRC, PTPRA | KDM4E 426/4885GAA 1401/4885GLA 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.